Check out the IMI-PainCare project publication, with the contribution of WeLab Barcelona. Link to full text: https://lnkd.in/edsw_BJN
“Biomarkers of nociceptive signal processing, combined with a pharmacometric modelling, will enable a more rational approach to selecting dose ranges and verifying target engagement. Combined with advances in classification of chronic pain conditions, these biomarkers are expected to accelerate analgesic drug development.”
IMI-Paincare has received funding from #IMI2 Joint undertaking under grant agreement No 777500. This Joint Undertaking receives support from the European Union HORIZON2020 research and innovation programme and EFPIA – European Federation of Pharmaceutical Industries and Associations
“Biomarkers of nociceptive signal processing, combined with a pharmacometric modelling, will enable a more rational approach to selecting dose ranges and verifying target engagement. Combined with advances in classification of chronic pain conditions, these biomarkers are expected to accelerate analgesic drug development.”
IMI-Paincare has received funding from #IMI2 Joint undertaking under grant agreement No 777500. This Joint Undertaking receives support from the European Union HORIZON2020 research and innovation programme and EFPIA – European Federation of Pharmaceutical Industries and Associations
